<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JAMA Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">JAMA Oncol</journal-id>
<journal-id journal-id-type="pmc">JAMA Oncol</journal-id>
<journal-title-group>
<journal-title>JAMA Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2374-2437</issn>
<issn pub-type="epub">2374-2445</issn>
<publisher>
<publisher-name>American Medical Association</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29596541</article-id>
<article-id pub-id-type="pmc">5885182</article-id>
<article-id pub-id-type="doi">10.1001/jamaoncol.2018.0089</article-id>
<article-id pub-id-type="publisher-id">coi180005</article-id>
<article-categories>
<subj-group specific-use="electronic" subj-group-type="category">
<subject>Research</subject>
</subj-group>
<subj-group specific-use="print" subj-group-type="domain">
<subject>Research</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Investigation</subject>
</subj-group>
<subj-group subj-group-type="online-first">
<subject>Online First</subject>
</subj-group>
<subj-group subj-group-type="online-only">
<subject>Online Only</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia</article-title>
<alt-title alt-title-type="headline">CSF Biomarkers of CNS Injury and Neurocognitive Outcomes in Children With Acute Lymphoblastic Leukemia</alt-title>
<alt-title alt-title-type="running-head">CSF Biomarkers of CNS Injury and Neurocognitive Outcomes in Children With Acute Lymphoblastic Leukemia</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Cheung</surname>
<given-names>Yin Ting</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khan</surname>
<given-names>Raja B.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="coi180005aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Wei</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brinkman</surname>
<given-names>Tara M.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="coi180005aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Edelmann</surname>
<given-names>Michelle N.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reddick</surname>
<given-names>Wilburn E.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pei</surname>
<given-names>Deqing</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="coi180005aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Panoskaltsis-Mortari</surname>
<given-names>Angela</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff7">
<sup>7</sup>
</xref>
<xref ref-type="aff" rid="coi180005aff8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Srivastava</surname>
<given-names>Deokumar</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheng</surname>
<given-names>Cheng</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robison</surname>
<given-names>Leslie L.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hudson</surname>
<given-names>Melissa M.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="coi180005aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="coi180005aff9">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pui</surname>
<given-names>Ching-Hon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="coi180005aff9">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Krull</surname>
<given-names>Kevin R.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="coi180005aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="coi180005aff4">
<sup>4</sup>
</xref>
</contrib>
</contrib-group>
<aff id="coi180005aff1"><label>1</label>Department of Epidemiology and Cancer Control, St Jude Children’s Research Hospital, Memphis, Tennessee</aff>
<aff id="coi180005aff2"><label>2</label>Department of Neurology, St Jude Children’s Research Hospital, Memphis, Tennessee</aff>
<aff id="coi180005aff3"><label>3</label>Department of Biostatistics, St Jude Children’s Research Hospital, Memphis, Tennessee</aff>
<aff id="coi180005aff4"><label>4</label>Department of Psychology, St Jude Children’s Research Hospital, Memphis, Tennessee</aff>
<aff id="coi180005aff5"><label>5</label>Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Denver</aff>
<aff id="coi180005aff6"><label>6</label>Department of Diagnosis Imaging, St Jude Children’s Research Hospital, Memphis, Tennessee</aff>
<aff id="coi180005aff7"><label>7</label>Pediatric Blood and Bone Marrow Transplant Program, University of Minnesota, Minneapolis</aff>
<aff id="coi180005aff8"><label>8</label>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis</aff>
<aff id="coi180005aff9"><label>9</label>Department of Oncology, St Jude Children’s Research Hospital, Memphis, Tennessee</aff>
<author-notes>
<title>Article Information</title>
<p><bold>Accepted for Publication:</bold> January 5, 2018.</p>
<corresp id="coi180005cor1"><bold>Corresponding Author:</bold> Kevin R. Krull, PhD, Department of Epidemiology and Cancer Control, St Jude Children’s Research Hospital, 262 Danny Thomas Pl, MS 735, Memphis, TN 38105 (<email xlink:href="kevin.krull@stjude.org">kevin.krull@stjude.org</email>).</corresp>
<p content-type="published-online"><bold>Published Online:</bold> March 29, 2018. doi:<uri content-type="doi">10.1001/jamaoncol.2018.0089</uri></p>
<p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Krull had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
<p><italic>Study concept and design:</italic> Cheung, Khan, Edelmann, Hudson, Krull.</p>
<p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p>
<p><italic>Drafting of the manuscript:</italic> Cheung, Edelmann, Srivastava, Cheng, Krull.</p>
<p><italic>Critical revision of the manuscript for important intellectual content:</italic> Cheung, Khan, Liu, Brinkman, Edelmann, Reddick, Pei, Panoskaltsis-Mortari, Cheng, Robison, Hudson, Pui, Krull.</p>
<p><italic>Statistical analysis:</italic> Cheung, Liu, Edelmann, Pei, Srivastava, Cheng, Krull.</p>
<p><italic>Obtained funding:</italic> Hudson, Krull.</p>
<p><italic>Administrative, technical, or material support:</italic> Reddick, Panoskaltsis-Mortari, Robison, Pui, Krull.</p>
<p><italic>Study supervision:</italic> Cheung, Krull.</p>
<p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> None reported.</p>
<p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by grant MH085849 from the <funding-source rid="sp1">National Institute of Mental Health</funding-source> (Dr Krull), grant CA195547 from the <funding-source rid="sp2">National Cancer Institute</funding-source> (Drs Robison and Hudson), and the <funding-source rid="sp3">American Lebanese Syrian Associated Charities</funding-source>.</p>
<p><bold>Role of the Funder/Sponsor:</bold> The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
<p><bold>Additional Contributions:</bold> Mary V. Relling, PharmD, St Jude Children’s Research Hospital, and her laboratory provided the pharmacokinetic data. Cara Kimberg, PhD, Cynthia Jones, MA, Deborah Stewart, MA, and Adrienne Studaway, MEd, St Jude Children’s Research Hospital, administered the neurocognitive tests. Joycelynn Butler, MS, and Eric Caron, APN, MSN, St Jude Children’s Research Hospital, extracted the data. None of these contributors were compensated for this work.</p>
</author-notes>
<pub-date iso-8601-date="2018-03-29T10:00" pub-type="epub">
<day>29</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>3</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
<volume>4</volume>
<issue>7</issue>
<elocation-id>e180089</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="final">
<day>21</day>
<month>12</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright 2018 American Medical Association. All Rights Reserved.</copyright-statement>
</permissions>
<self-uri content-type="pdf-version" xlink:href="jamaoncol-4-e180089.pdf">jamaoncol-4-e180089.pdf</self-uri>
<self-uri content-type="roundpoint" xlink:href="https://app.jamanetwork.com/?doi=10.1001/jamaoncol.2018.0089"></self-uri>
<self-uri content-type="silverchair" xlink:href="https://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.0089"></self-uri>
<abstract abstract-type="teaser">
<p>This cohort study evaluates the association of cerebrospinal fluid biomarkers of brain injury with short- and long-term outcomes and genetic polymorphisms in children receiving chemotherapy for acute lymphoblastic leukemia.</p>
</abstract>
<abstract abstract-type="key-points">
<title>Key Points</title>
<sec id="ab-coi180005-1">
<title>Question</title>
<p>Are cerebrospinal fluid biomarkers of brain injury associated with treatment-related neurotoxic effects in children who receive chemotherapy for acute lymphoblastic leukemia?</p>
</sec>
<sec id="ab-coi180005-2">
<title>Findings</title>
<p>In this cohort study of 235 children with acute lymphoblastic leukemia, methotrexate exposure was positively correlated with markers of neuronal damage, and markers of demyelination and axonal damage were associated with as much as a 70% higher risk of developing leukoencephalopathy during therapy, worse long-term frontal lobe white matter integrity, and poorer neurocognitive function. Carriers of the Val allele in the <italic>COMT</italic> gene demonstrated greater biomarker level elevations after methotrexate exposure than did carriers of the Met allele.</p>
</sec>
<sec id="ab-coi180005-3">
<title>Meaning</title>
<p>Monitoring cerebrospinal fluid biomarkers and screening for genetic mediators of brain injury may help in identifying survivors at risk for abnormal neurodevelopment.</p>
</sec>
</abstract>
<abstract>
<sec id="ab-coi180005-4">
<title>Importance</title>
<p>Little is known about treatment-related neurotoxic mechanisms in children with acute lymphoblastic leukemia (ALL) treated with chemotherapy only.</p>
</sec>
<sec id="ab-coi180005-5">
<title>Objective</title>
<p>To examine concentration of cerebrospinal fluid (CSF) biomarkers of brain injury at ALL diagnosis and during cancer therapy and to evaluate associations with long-term neurocognitive and neuroimaging outcomes and relevant genetic polymorphisms.</p>
</sec>
<sec id="ab-coi180005-6">
<title>Design, Setting, and Participants</title>
<p>This prospective cohort study included 235 patients with ALL who received a chemotherapy-only protocol. Patients provided CSF samples after diagnosis and throughout treatment. At 5 or more years after the diagnosis, 138 (69.7%) of 198 eligible survivors participated in long-term follow-up assessments. Children were treated from June 1, 2000, through October 31, 2010. Follow-up was completed on October 21, 2014, and data were analyzed from August 1, 2015, through September 30, 2016.</p>
</sec>
<sec id="ab-coi180005-7">
<title>Exposures</title>
<p>Plasma concentration of high-dose intravenous methotrexate sodium and number of triple intrathecal chemotherapy injections.</p>
</sec>
<sec id="ab-coi180005-8">
<title>Main Outcomes and Measures</title>
<p>The CSF samples were assayed at 5 points from diagnosis to reinduction for biomarkers of myelin degradation (myelin basic protein [MBP]), neuronal damage (nerve growth factor [NGF] and total and phosphorylated tau protein), astrogliosis (glial fibrillary acidic protein [GFAP]), and neuroinflammation (chitotriosidase). DNA was genotyped for polymorphisms in drug metabolism, oxidative stress, and neurodevelopment. Leukoencephalopathy was evaluated by brain imaging. At 5 or more years after the diagnosis, survivors completed neurocognitive testing and brain imaging of white matter integrity.</p>
</sec>
<sec id="ab-coi180005-9">
<title>Results</title>
<p>Among the 235 patients with CSF samples (120 boys [51.1%] and 115 girls [48.9%]; mean [SD] age at diagnosis, 6.8 [4.7] years), MBP and GFAP levels were elevated at baseline and through consolidation. The number of intrathecal injections was positively correlated with NGF level increase at consolidation (<italic>r</italic> = 0.19; <italic>P</italic> = .005). Increases in GFAP (risk ratio [RR], 1.23; 95% CI, 1.09-1.40), MBP (RR, 1.06; 95% CI, 1.01-1.11), and total tau (RR, 1.76; 95% CI, 1.11-2.78) levels were associated with a higher risk for leukoencephalopathy and higher apparent diffusion coefficient in frontal lobe white matter 5 years after diagnosis (standardized estimate, 0.05; <italic>P</italic> &lt; .001). Increase in total tau at consolidation was associated with worse attention (omissions <italic>z</italic> score estimate, −0.20; <italic>P</italic> = .04).</p>
</sec>
<sec id="ab-coi180005-10">
<title>Conclusions and Relevance</title>
<p>Glial injury may be present at diagnosis of ALL. Neuronal injury was associated with intrathecal chemotherapy. The CSF biomarkers may be useful in identifying individuals at risk for worse neurologic outcomes, particularly those with genetic susceptibility to poor brain function.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source id="sp1">National Institute of Mental Health</funding-source>
</award-group>
<award-group>
<funding-source id="sp2">National Cancer Institute</funding-source>
</award-group>
<award-group>
<funding-source id="sp3">American Lebanese Syrian Associated Charities</funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>